Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Gouji
G
Toyokawa
Fumihiko
F
Hirai
Eiko
E
Inamasu
Tsukihisa
T
Yoshida
Kaname
K
Nosaki
Tomoyoshi
T
Takenaka
Masafumi
M
Yamaguchi
Takashi
T
Seto
Mitsuhiro
M
Takenoyama
Yukito
Y
Ichinose
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002227:Carbazoles / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D000077547:Crizotinib; D018432:Drug Resistance, Multiple; D005260:Female; D050939:Gene Fusion; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D009154:Mutation; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
D002227:Carbazoles; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C582670:alectinib